Effective Nose-to-Brain Delivery of Blood-Brain Barrier Impermeant Anti-IL-1β Antibody via the Minimally Invasive Nasal Depot (MIND) Technique
Valentina Di Francesco, Andy J. Chua, Benjamin S. Bleier, Mansoor M. Amiji · 2024
Read Effective Nose-to-Brain Delivery of Blood-Brain Barrier Impermeant Anti-IL-1β Antibody via the Minimally Invasive Nasal Depot (MIND) Technique by Valentina Di Francesco, Andy J. Chua, Benjamin S. Bleier, Mansoor M. Amiji (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11660045.txt.
Description
Valentina Di Francesco and co-authors present a 2024 study of a nose-to-brain route for delivering antibody drugs. The blood-brain barrier blocks biologics from reaching the brain, which stalls treatment of brain inflammation and degeneration. Their method places a drug depot inside the nose through a minimally invasive step.
In mice with brain inflammation triggered by a bacterial toxin, the depot delivered a full-length antibody against interleukin-1 beta. Brain levels of that inflammatory signal fell, and the activation of microglia, the brain's immune cells, eased. The route beat standard intravenous delivery on both counts. The authors argue the approach could open the brain to a class of drugs now locked out. The technique has prior clinical validation behind it.
Catalog record
| CREATOR | Valentina Di Francesco, Andy J. Chua, Benjamin S. Bleier, Mansoor M. Amiji |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |